Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Year: 2025
Type: erratum
Source: Journal of Clinical Oncology
DOI: 10.1200/jco-25-00466
Authors: Matthew S. Davids, Christine E. Ryan, Benjamin L. Lampson, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Jennifer L. Crombie, Austin I. Kim, Matthew Weinstock, Josie Montegaard, Heather A. Walker, Claire Greenman, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Steve Lo, Adam J. Olszewski, Jon E. Arnason, Inhye E. Ahn, Jennifer R. Brown
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4408561896